definiens: means, with respect to the Licensed Products in e ach of the United States, the EU Market and China, the existen ce of objective circumstances arising after the Eff ective Date with respect to such Market ( other than a Safety / Ef ficacy Issue ), as a result of which a company in th e biopharmaceutical industry would reasonably be expe cted to elect not to continue to fund or conduct th e development or commercialization of the Licensed Pr oducts for such Market in light of the overall busi ness case with respect to the Licensed Products in such Marke t, taking into account relevant commercial factors, including the additional time and Development costs required to obtain or maintain Regulatory Approval in such M arket, the product profile, the competitiveness of the mar ketplace and the proprietary position of the Licens ed Products and other commercial factors customarily considered in a business case analysis ( e.g., forecasted sale s volumes, net selling price per unit, cost of goods per unit, commercialization costs and other data indicating anticipated revenues in such Market or country, as applicable ( including, with respect to the EU Market, for each Major European Market ) )